Skandinaviska Enskilda Banken Ab (Publ) Viking Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 20,746 shares of VKTX stock, worth $632,338. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,746
Previous 28,418
27.0%
Holding current value
$632,338
Previous $1.8 Million
53.64%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
471Shares Held
66.4MCall Options Held
5.88MPut Options Held
3.83M-
Vanguard Group Inc Valley Forge, PA10.2MShares$310 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$184 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$150 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$79.1 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$65.8 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.34B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...